Taubenhansl, Clara and Ortmann, Olaf and Gerken, Michael and Inwald, Elisabeth C. and Klinkhammer-Schalke, Monika (2020) Guideline-concordant chemotherapy in patients with hormone receptor-positive and node-positive, early breast cancer leads to better overall and metastases-free survival with limited benefit in elderly patients. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 301 (2). pp. 573-583. ISSN 0932-0067, 1432-0711
Full text not available from this repository. (Request a copy)Abstract
Purpose The German guideline for breast cancer recommends using chemotherapy (CHT) in patients with hormone receptor-positive and node-positive, invasive breast cancer. The aim of this study was to analyse the effects of CHT in this patient group on overall survival (OS) and distant metastases-free survival (DMFS), especially considering the 70-year threshold. Methods 1772 patients from the clinical cancer registry Regensburg (Germany) with hormone receptor-positive and node-positive, invasive breast cancer diagnosed between 2003 and 2013 were analysed in a retrospective cohort study. OS and DMFS were evaluated by means of Kaplan-Meier and multivariable Cox-regression method. Results were further examined according to age at diagnosis. Results The comparison of 1544 patients with CHT to 228 patients without CHT showed a significant benefit for CHT regarding 5-year OS (91.3% vs. 76.8%) and 5-year DMFS (86.7% vs. 74.4%, both p < 0.001). Likewise, better OS and DMFS were seen in patients aged < 70 years using CHT compared to patients without CHT of the same age. Patients aged >= 70 years with CHT had a minimal benefit regarding 5-year OS compared to patients without CHT, but no advantage considering DMFS. All results were confirmed in multivariable analyses except for patients being >= 70 years of age. Conclusion Patients with hormone receptor-positive and node-positive, invasive breast cancer benefit from chemotherapy with regard to a significantly better overall and distant metastases-free survival, although chemotherapy use in patients aged >= 70 years results in a smaller benefit considering OS and no benefit considering DMFS.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ADJUVANT CHEMOTHERAPY; ENDOCRINE THERAPY; POSTMENOPAUSAL WOMEN; OLDER; COMORBIDITY; PREVALENCE; YOUNGER; SCORE; RISK; Breast cancer; Hormone and node positive; Chemotherapy; Elderly patients; Overall survival; Distant metastases-free survival |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Frauenheilkunde und Geburtshilfe (Schwerpunkt Frauenheilkunde) Medicine > Zentren des Universitätsklinikums Regensburg > Tumorzentrum e.V. |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 30 Mar 2021 11:55 |
| Last Modified: | 30 Mar 2021 11:55 |
| URI: | https://pred.uni-regensburg.de/id/eprint/45244 |
Actions (login required)
 |
View Item |
